Clinical trials
Heart Failure trials in Finland
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
57 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 4 |
| 2011 | 7 |
| 2012 | 2 |
| 2013 | 4 |
| 2014 | 5 |
| 2016 | 3 |
| 2018 | 5 |
| 2019 | 2 |
| 2020 | 2 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 5 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 35 |
| Recruiting | 11 |
| Terminated | 7 |
| Unknown status | 3 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bayer | 8 |
| Novartis Pharmaceuticals | 8 |
| AstraZeneca | 4 |
| Abbott Medical Devices | 3 |
| Medtronic Cardiac Rhythm and Heart Failure | 3 |
| Ottawa Heart Institute Research Corporation | 3 |
| Amgen | 2 |
| Helsinki University Central Hospital | 2 |
| ResMed | 2 |
| Turku University Hospital | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Heart Failure | 57 |
| Ventricular Dysfunction, Left | 5 |
| Cardiovascular Diseases | 4 |
| Coronary Artery Disease | 4 |
| Atrial Fibrillation | 3 |
| Diabetes Mellitus, Type 2 | 3 |
| Cardiomyopathies | 2 |
| Heart Diseases | 2 |
| Myocardial Infarction | 2 |
| Renal Insufficiency | 2 |
Trials
Showing 26 to 50 of 57. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.